While acute hepatitis B infection is often resolved by the immune system, CHB occurs when the body's defences are unable to ...

Scientists from the Institut Pasteur, in collaboration with Kumamoto University in Japan, have assessed a new rapid ...

Researchers are now exploring strategies to silence cccDNA, aiming for a functional cure and offering hope to millions of patients worldwide. Hepatitis B virus infection remains one of the leading ...

Precision BioSciences (DTIL) announced that the U.S. Food and Drug Administration or FDA has cleared the Investigational New Drug application ...

Hepatitis B is a liver infection caused by the hepatitis B virus (HBV), and long-term hepatitis B infections that last longer ...

The push to cure hepatitis B kicked off in earnest about 10 years ago, when several leading HBV scientists began convening scientific workshops aimed at developing a cure-focused action plan ...

It is notable that even in HBV patients who have achieved a functional cure, chronic HBV can be reactivated by suppressing the immune system 4. We hypothesize that reducing antigen levels to ...

An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a phase 2 trial, raising hopes of a “functional cure” for the widespread disease.

and the opportunities currently under development to achieve the goal of HBV cure (bottom). cccDNA, covalently closed circular DNA; 3D, three-dimensional; DCs, dendritic cells; FNAs, fine-needle ...

With JNJ-3989, GSK hopes to develop a sequential regimen with bepirovirsen that will improve the functional cure rate. HBV affects almost 300 million people worldwide, according to GSK ...

PBGENE-HBV is Precision’s lead wholly owned in vivo gene editing program designed to cure chronic hepatitis B by eliminating cccDNA, the key source of replicating hepatitis B virus HBV ...